Table 5.
Patients with BS type 3: Comparison between patients with CKD and patients with normal GFR
| Variable | CKD Stages 2–5, n=19 | eGFR>90 ml/min per 1.73 m2, n=58 | P Value | |
|---|---|---|---|---|
| Birth weight, g | 3200 (2810–3450)10 | 2995 (2530–3380)24 | 0.50 | |
| Age at diagnosis, yr | 0.41 (0.16–8.00) | 1.45 (0.39–15.75) | 0.18 | |
| Age at last follow-up, yr | 20 (12–42) | 13 (6–26) | 0.02 | |
| NSAIDs, n (%) | Yes | 14 (79) | 29 (50) | 0.10 |
| No | 5 (21) | 29 (59) | ||
| Treatment duration, yr | 5.2 (3.2–14.25)2 | 6 (3.3–9.2)3 | 0.53 | |
| Other renal and urological abnormalities (excluding nephrocalcinosis) | Yes | 5 | 4 | 0.24 |
| No | 12 | 27 | ||
| Hypokalemia <3 with treatment | Yes | 8 | 20 | 1 |
| No | 8 | 21 |
Quantitative values are expressed as medians and interquartile intervals. Superscript values correspond to the number of missing data. NSAIDs, nonsteroidal anti-inflammatory drugs.